Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 33Carcinoma, Non-Small-Cell Lung 19Squamous Cell Carcinoma of Head and Neck 18Esophageal Neoplasms 17Uterine Cervical Neoplasms 11Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 11Pancreatic Neoplasms 9Oropharyngeal Neoplasms 8Esophageal Squamous Cell Carcinoma 6Carcinoma, Squamous Cell 6Stomach Neoplasms 4Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Colorectal Neoplasms 4Carcinoma 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Pathologic Complete Response 3Hypopharyngeal Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms by Site 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lung Neoplasms 2Locally Advanced Malignant Neoplasm 2Laryngeal Neoplasms 2

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Resectable Esophageal Cancer × Chemoradiotherapy × Clear all
NCT07385664 2026-02-04

FAIR

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
66 enrolled
Gastrointestinal

Resectable Esophageal Cancer

NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡